Lancaster Cancer Center

Lancaster, Pennsylvania 17605-0396

0 studies enrolling now · 12 studies all time

What they study most

Advanced Breast Cancer, Breast Cancer, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), First Line Non-Small Cell Lung Cancer, Leukemia, Myeloid, Acute, Lung Cancer, Metastatic Breast Cancer, Metastatic Prostate Cancer, Multiple Myeloma, Myelodysplastic Syndromes, Pancreatic Cancer

Studies at this site

• Connect® MM- The Multiple Myeloma Disease Registry — Stopped early
• Connect® Myeloid Disease Registry — Stopped early
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• Palbociclib in Real World Practice — Completed
• informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia — Completed
• Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation — Completed
• Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry — Completed
• Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer — Completed
• Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer — Completed
• Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer — Withdrawn before enrolling
• Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer — Completed
• Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) — Stopped early